Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson's disease (vol 236, pg 1701, 2019)

被引：0
|
作者：
Cherian, Ajeesh Koshy [1 ]
Kucinski, Aaron [1 ]
Wu, Ryan [1 ]
de Jong, Inge E. M. [2 ]
Sarter, Martin [1 ]
机构：
[1] Univ Michigan, Dept Psychol, 530 Church St, Ann Arbor, MI 48109 USA
[2] H Lundbeck & Co AS, Div Neurodegenerat, Valby, Denmark
来源：
PSYCHOPHARMACOLOGY | 2020年 / 237卷 / 01期
关键词：
D O I：
10.1007/s00213-019-05375-0
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
After publication of this paper, the authors determined that the “Acknowledgments” section was omitted. Below is the “Acknowledgments” statement.
引用
收藏
页码：289 / 289
页数：1
相关论文
共 38 条
  • [31] Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease (vol 8, 10722, 2018)
    Chen, Shuchun
    Yu, Seong-Jin
    Li, Yazhou
    Lecca, Daniela
    Glotfelty, Elliot
    Kim, Hee Kyung
    Choi, Ho-Il
    Hoffer, Barry J.
    Greig, Nigel H.
    Kim, Dong Seok
    Wang, Yun
    SCIENTIFIC REPORTS, 2018, 8
  • [32] THE FIRING ACTIVITY OF PYRAMIDAL NEURONS IN MEDIAL PREFRONTAL CORTEX AND THEIR RESPONESE TO 5-HYDROXYTRYPTAMINE-1A RECEPTOR STIMULATION IN A RAT MODEL OF PARKINSON'S DISEASE (vol 162, pg 1091, 2009)
    Wang, S.
    Zhang, Q. J.
    Liu, J.
    Wu, Z. H.
    Ali, U.
    Wang, Y.
    Chen, L.
    Gui, Z. H.
    NEUROSCIENCE, 2012, 202 : 492 - 493
  • [33] Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease
    Chen, Shuchun
    Yu, Seong-Jin
    Li, Yazhou
    Lecca, Daniela
    Glotfelty, Elliot
    Kim, Hee Kyung
    Choi, Ho-Il
    Hoffer, Barry J.
    Greig, Nigel H.
    Kim, Dong-Seok
    Wang, Yun
    SCIENTIFIC REPORTS, 2018, 8
  • [34] Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
    Shuchun Chen
    Seong-Jin Yu
    Yazhou Li
    Daniela Lecca
    Elliot Glotfelty
    Hee Kyung Kim
    Ho-Il Choi
    Barry J. Hoffer
    Nigel H. Greig
    Dong Seok Kim
    Yun Wang
    Scientific Reports, 8
  • [35] RETRACTED: Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinson's disease in rat model? (Retracted article. See vol. 37, pg. 557, 2018)
    Ahmed, H. H.
    Salem, A. M.
    Atta, H. M.
    Ghazy, M. A.
    Aglan, H. A.
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2014, 33 (12) : 1217 - 1231
  • [36] Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease (vol 56, pg 48, 2013)
    Febbraro, Fabia
    Sahin, Gurdal
    Farran, Aina
    Soares, Sofia
    Jensen, Paul H.
    Kirik, Deniz
    Romero-Ramos, Marina
    NEUROBIOLOGY OF DISEASE, 2013, 58 : 191 - 191
  • [37] Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
    Shuchun Chen
    Seong-Jin Yu
    Yazhou Li
    Daniela Lecca
    Elliot Glotfelty
    Hee Kyung Kim
    Ho-Il Choi
    Barry J. Hoffer
    Nigel H. Greig
    Dong Seok Kim
    Yun Wang
    Scientific Reports, 8
  • [38] RETRACTION: PKM2 overexpression protects against 6-hydroxydopamine-induced cell injury in the PC12 cell model of Parkinson's disease via regulation of the brahma-related gene 1/STAT3 pathway (Retraction of Vol 9, Pg 14834, 2019)
    Fisher, Laura
    RSC ADVANCES, 2021, 11 (09) : 5020 - 5020
1234